Article citationsMore>>
Kochanek, M., Schalk, E., von Bergwelt-Baildon, M., Beutel, G., Buchheidt, D., Hentrich, M., Henze, L., Kiehl, M., Liebregts, T., von Lilienfeld-Toal, M., Classen, A., Mellinghoff, S., Penack, O., Piepel, C. and Boll, B. (2019) Management of Sepsis in Neutropenic Cancer Patients: 2018 Guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO). Annals of Hematology, 98, 1051-1069.
https://doi.org/10.1007/s00277-019-03622-0
has been cited by the following article:
-
TITLE:
Non-Neutropenic Sepsis in Cancer Patients: The Luminal Obstruction Syndrome
AUTHORS:
Tamás Kullmann, Dóra Füzi, Tamás Pintér
KEYWORDS:
Sepsis, Biliary Sepsis, Urosepsis, Bronchogenic Sepsis, Solid Cancer
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.10 No.10,
September
29,
2019
ABSTRACT: Background: Neutropenic sepsis is a frequent
complication of cytotoxic chemotherapy delivered for cancer patients. Its
management is well determined by clinical
guidelines. Non-neutropenic sepsis is another potential complication in
cancer patients. Its management is less established in the medical literature. Materials
and Methods: Three cases are presented
to illustrate favourable evolution of
non-neutropenic biliary-, uro- and bronchogenic-sepsis in cancer patients with poor prognosis. Results: All three patients had a survival over six months after the management of the
septic complication. Two of them received
subsequent systemic anticancer treatment. Conclusions: Survival
benefit offered by the management of cancer-related non-neutropenic
sepsis may be comparable to the benefit obtained by systemic anticancer
treatments. Cost-effectiveness of sepsis management may be better than that of
anticancer treatments.
Related Articles:
-
Arezoo Omati, Kambiz Davari, Borhan Shokrolahi
-
Sarah Tasneem, Lester Lipsky, Reda Ammar, Howard Sholl
-
Ananda Prasad Panta, Ram Prasad Ghimire, Dinesh Panthi, Shankar Raj Pant
-
Mohamed S. El Naschie
-
R. Douglas Martin, Shengyu Zhang